Skip to main content

So Complex

Newsweek discusses some of "life's complexities," namely epigenetics and systems biology.

One article takes a look at epigenetics and its role in cancer. A few epigenetic cancer drugs have been approved by FDA, such as Vidaza and Zolinza, but "first-generation epigenetic drugs have not included a home run like Gleevec," the story says.

In that same issue, Lee Hood describes his vision of P4 medicine — predictive, personalized, preventive, and participatory. Soon, he says, with just a pinprick of blood, thousands of tests may be run and the results sent to both the patient and the doctor. "The new P4 medicine will eventually lead to a universal democratization of health care, bringing to billions the fundamental right of health, unimaginable even a few years ago," Hood writes. He points out, though, that to reach this goal, changes will have to be made to medical education, research, and to the insurance and pharmaceutical industries.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.